Despite a 16% revenue increase, Canaccord Genuity Group Inc (CCORF) faces profitability hurdles due to rising expenses and US ...

Aurora Innovation, Inc. (NASDAQ: AUR) today announced David Maday, Chief Financial Officer, will participate in a virtual ...

Canaccord Genuity has downgraded Pliant (PLRX) to hold following news that the company has paused a clinical trial for its ...

In a report released yesterday, Alexander Bedwany from Canaccord Genuity reiterated a Buy rating on Kodal Minerals (KOD – Research Report), ...

Similarly, Canaccord Genuity maintained a Buy rating on Travere and increased the price target to $45, reflecting the firm's expectations for the peak revenue of SAGE, another product in Travere's ...

Canaccord Genuity analyst Alexander Bedwany reiterated a Sell rating on South32 Ltd. (S32 – Research Report) yesterday and set a price target ...

Fintel reports that on February 10, 2025, Canaccord Genuity downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Investment analysts at Ventum Cap Mkts dropped their FY2025 earnings per share (EPS) estimates for shares of Canaccord ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Canaccord Genuity Group in a note issued to investors on Monday, MarketBeat reports.

Analysts at Canaccord Genuity slightly raised their target price on Celtic from 202.0p to 208.0p on Tuesday, stating the firm ...

A big dividend yield for a few years doesn't mean much if it can't be sustained. While Canaccord Genuity Group is not profitable, it is paying out less than 75% of its free cash flow, which means that ...